Mefloquine (Brand Name Lariam®) is an anti-malarial drug which is FDA-approved for use in regions where local strains of malaria have developed a resistance to other anti-malarial agents such as chloroquine. ASD(HA) Memorandum, Policy Memorandum on the Use of Mefloquine (Lariam®) as Malaria Prophylaxis, 4 Sep 09 states that “Mefloquine should only be used for personnel with contraindications to doxycycline and who do not have any contraindications to the use of mefloquine”.
Below, we have provided information on Mefloquine/Lariam®, including clinical guidance, policies and directives, training material, and other resources, to assist healthcare providers and Service members and their families.
Table of Contents
Policies and Directives
DoD / Joint Forces
- DASG Memorandum, Updated Guidance on Use of Mefloquine (Lariam® ) for Malaria Prophylaxis, 2 Feb 09
- Army G1, Personnel Policy Guidance (PPG) for Contingency Operations in Support of GWOT paragraph 7-6c(1) Malaria Chemoprophylaxis
VA (Veterans Administration)
Other Related Information
- Mefloquine Prescriptions in the Presence of Contraindications: Prevalence Among US military Personnel in Afghanistan, 2007, Pharmacoepidemiology and Drug Safety Volume 19 Issue 2, Pages 206 – 210, 2010
- Prevalence of Contraindications to Mefloquine Use Among USA Military Personnel Deployed to Afghanistan, Malaria Journal 2008, 7:30, 11 Feb 08
- Vestibular Dysfunction Among OEF/OIF Returnees PowerPoint Presentation, AFEB Meeting, 21 Sep 04
- The Risk of Severe Depression, Psychosis or Panic Attacks with Prophylactic Antimalarials, Drug Safety 2004; 27 (3): 203-213
- Tolerability of Malaria Chemoprophylaxis in Non-immune Travelers to Sub-Saharan Africa: Multicentre, Randomised, Double Blind, Four Arm Study; BMJ Vol 327, 8 Nov 03